Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03769285
Other study ID # SPRINTR-Pilot
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 3, 2018
Est. completion date December 2023

Study information

Verified date March 2023
Source Women's College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal trial to examine the efficacy and safety of nicotinamide for prevention of keratinocyte carcinoma in solid organ transplant recipients. This pilot trial will transition into the pivotal trial if all feasibility targets are met.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years old 2. Kidney, liver, heart, or lung transplant at least two years ago 3. History of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ 4. Currently immunosuppressed with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus) 5. Able to attend follow-up visits 6. Able to speak and understand English (only for cognitive substudy) Exclusion Criteria: 1. Use of mTOR inhibitor (sirolimus, everolimus) within the past 12 weeks 2. Biopsy-confirmed acute rejection episode within the past 12 weeks 3. Active liver disease (elevated AST or ALT >3 times normal) 4. Severe renal failure (estimated glomerular filtration rate <20 mL/min/1.73 m2) 5. Current carbamazepine or primidone use 6. Pregnancy and lactation 7. Gorlin syndrome or other genetic skin cancer syndrome 8. Solid organ or hematologic malignancy, invasive Stage II melanoma, Merkel cell carcinoma, or metastatic skin cancer within the past five years, or invasive Stage I melanoma within the past two years 9. Untreated localized skin cancer (invasive squamous cell carcinoma, basal cell carcinoma, or keratoacanthoma) at baseline (the patient can enrol after skin cancer treatment) 10. Use of nicotinamide or niacin (250 mg or more daily) within the past 12 weeks 11. Use of field therapy for actinic keratoses within the past 12 weeks 12. Initiation of systemic chemoprevention within the past 12 weeks

Study Design


Intervention

Drug:
Nicotinamide
Oral nicotinamide (500 mg) twice daily for at least 52 weeks
Placebo oral capsule
Matching placebo taken twice daily for at least 52 weeks

Locations

Country Name City State
Canada Toronto General Hospital, University Health Network Toronto Ontario

Sponsors (5)

Lead Sponsor Collaborator
Women's College Hospital Canadian Institutes of Health Research (CIHR), Natural Life Nutrition, NOW Foods, The Kidney Foundation of Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility (pertaining to patient recruitment) Proportion of patients who consent to data linkage to provincial administrative databases 1 year
Primary Feasibility (pertaining to appropriateness of eligibility criteria) Reasons for exclusion of screened patients 1 year
Primary Feasibility (pertaining to adherence to intervention) Proportion of capsules returned, reasons for non-adherence 1 year
Primary Feasibility (pertaining to adherence to follow-up assessments) Proportion of missed assessments and incomplete questionnaire data variables, proportion of patients who withdraw from the trial, patient perception of trial participation 1 year
Primary Feasibility (pertaining to data linkage) Proportion of patients who consent to data linkage to provincial administrative databases 1 year
Primary Preliminary pooled keratinocyte carcinoma event rate Pooled keratinocyte carcinoma event rate to be used for sample size re-estimation in the pivotal trial. 1 year
Primary Drug interactions Proportion of patients with a clinically relevant increase in cyclosporine or tacrolimus blood concentration at 1 week. An increased level will be classified as clinically relevant if the transplant physician reduces the immunosuppressant dose in response to the increased drug level. 1 week
Primary Drug interactions Proportion of patients with a clinically relevant increase in cyclosporine or tacrolimus blood concentration at 2 weeks. This measurement will be dropped if all cases of clinically relevant drug interactions manifest at 1 week in the first 20 enrolled participants. 2 weeks
Primary Serious adverse events Descriptive tabulation (preliminary safety) 1 year
Secondary Feasibility of recruiting for neurocognitive substudy Proportion of enrolled participants who consent to participate in the neurocognitive substudy 1 year
Secondary Baseline prevalence of cognitive impairment (substudy) Montreal Cognitive Assessment (MoCA) score <26, scored out of 30. 1 year
Secondary Pooled standard deviation of MoCA test scores (substudy) Montreal Cognitive Assessment (MoCA), raw scores are scored out of 30, with a higher score representing better cognitive function 1 year
Secondary Pooled standard deviation of Hopkins Verbal Learning Test - Revised scores (substudy) Hopkins Verbal Learning Test - Revised, a memory test scored out of 60, with a higher score representing better memory 1 year
Secondary Pooled standard deviation of Trail Making A and B test scores (substudy) Trail Making A and B, a visual attention test. This records the time (in seconds) to completion, with a faster time representing better cognitive function 1 year
Secondary Pooled standard deviation of Controlled Oral Word Association test scores (substudy) Controlled Oral Word Association, a verbal fluency test, measures the production of words belonging to the same letter. This records total number of words produced, with a higher number representing better verbal fluency. 1 year
Secondary Pooled standard deviation of Animal Naming Task scores (substudy) Animal Naming Task, a verbal fluency task, measures the total number of animals named in one minute, with a higher number representing better verbal fluency 1 year
Secondary Pooled standard deviation of cognitive test scores (substudy) Wechsler Adult Intelligence Scale - Revised, Digit Span subtest, a number sequencing memory test, measures the number of correctly repeated sequences with maximum score of 48. The higher score represents better cognitive function 1 year
Secondary Pooled standard deviation of serum phosphate levels (substudy) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02743832 - A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma. N/A
Active, not recruiting NCT02229656 - Olaparib and Radiotherapy in Head and Neck Cancer Phase 1
Completed NCT00389727 - Simultaneous Integrated Boost (SIB)- IMRT Phase 2
Recruiting NCT02328391 - STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE N/A
Completed NCT00534950 - Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck N/A
Completed NCT00875381 - Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin N/A
Terminated NCT00073450 - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) Phase 2
Terminated NCT01441128 - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01362127 - Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia Phase 2
Completed NCT00240682 - Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Phase 2
Terminated NCT02254044 - Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus Phase 1
Active, not recruiting NCT00829192 - Phase II AK Study in Organ Transplant Patients Phase 2
Completed NCT00539630 - TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN Phase 3
Completed NCT00313027 - Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation N/A
Recruiting NCT04564989 - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Not yet recruiting NCT06094829 - Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
Recruiting NCT04481256 - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY N/A
Active, not recruiting NCT02664935 - National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer Phase 2
Terminated NCT02438995 - Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 1